UQ introduces nanoscale imaging system to watch proteins in live neurons, advancing Alzheimer’s and Parkinson’s drug discovery

Scientists at the University of Queensland revealed a novel imaging platform capable of following single disease‑associated proteins within living neurons, a feature that may speed up the initial phases of drug development for Alzheimer’s and Parkinson’s diseases.

The platform, named NASTIC (Nanoscale Spatiotemporal Indexing Clustering), merges super‑resolution microscopy with sophisticated computational indexing to chart the motion and interactions of individual protein molecules as they occur. By giving each protein its own spatiotemporal fingerprint, researchers can watch these molecules aggregate, spread apart, or alter shape inside the intricate setting of a living brain cell.

Since numerous neurodegenerative diseases stem from the misfolding and clumping of particular proteins—beta‑amyloid and tau in Alzheimer’s, or alpha‑synuclein in Parkinson’s—observing these mechanisms in a living neuron gives a direct glimpse of the initial pathological steps. The tool lets scientists evaluate how experimental compounds influence protein dynamics, delivering a more physiologically accurate read‑out than conventional biochemical assays that depend on purified proteins or fixed samples.

This advancement comes as the drug pipeline for brain disorders suffers from high attrition, frequently blamed on the challenge of converting results from cell cultures or animal models into human outcomes. By maintaining the native cellular environment, NASTIC aims to cut down false leads and concentrate effort on compounds that clearly alter protein dynamics in the relevant context.

Researchers at the University of Queensland intend to share the system with partner laboratories around the globe and have already joined forces with biotech companies to embed NASTIC into high‑throughput screening pipelines. Should it prove effective, the method could compress the interval between target validation and pre‑clinical testing, raising prospects for quicker availability of potent treatments to those confronting neurodegenerative diseases.